Novavax, Inc. focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company was founded in 1987 and is based in Gaithersburg, Maryland.
NVAX Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for NVAX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Novavax Inc ranked in the 98th percentile in terms of potential gain offered. Our DCF model suggests the stock is undervalued by 22116%; returns of such proportions should be viewed with some skepticism, though. The most interesting components of our discounted cash flow analysis for Novavax Inc ended up being:
The business' balance sheet suggests that 5% of the company's capital is sourced from debt; this is greater than only 17.74% of the free cash flow producing stocks we're observing.
Novavax Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -17.58. This coverage rate is greater than that of only 5.84% of stocks we're observing for the purpose of forecasting via discounted cash flows.
As a business, Novavax Inc experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than just 0% of stocks generating free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Novavax Inc? See THC, BMRN, KMDA, VRTX, and AMEH.
Novavax’s ([[NVAX]] -2.2%) Phase 3 trial of its COVID-19 vaccine candidate, NVX-CoV2373 has received drop-out requests from some participants who are 65 or older, after New York announced vaccination program for the above age group with one of two authorized vaccines, by Pfizer and Moderna, reported Washington Post.One Long Island physician told...
South Korea may secure additional coronavirus vaccines for 20 million people from U.S. drugmaker Novavax Inc, President Moon Jae-in said, according to a statement from the presidential office on Wednesday. Novavax entered into a development and supply agreement for its vaccine with South Korea's SK bioscience Co last year, according to a statement in August. Moon visited SK bioscience's work site on Wednesday and said that the agreement between Novavax and SK bioscience "raised the possibility of securing vaccines for an additional 20 million people," the statement said.
Global Corona Virus Vaccines Market: Overview COVID-19 refers to a viral infection occurred due to a corona virus named SARS-CoV-2. This virus attacks the respiratory tract of an individual. The COVID-19 virus is communicable disease and can spread due to direct